Uncommon Case of Hemophagocytic Lymphohistiocytosis as the First Presentation of Systemic Lupus Erythematosus Authors: Swetha Tummala, Andy Wu, Yen-Nan Lin, Tiarra Price, Anthony Demetris, Stela Celaj Published: 2026 ABSTRACT ABSTRACTHemophagocytic lymphohistiocytosis secondary to systemic lupus erythematosus (SLE) is a potentially fatal condition that is frequently misdiagnosed, particularly when its occurrence is the first manifestation of SLE. Diagnosis is often delayed due to overlapping clinical and laboratory findings with infections and autoimmune diseases. We report a case of a young, healthy woman with hemophagocytic lymphohistiocytosis as the first manifestation of SLE. Early multispecialist involvement, comprehensive laboratory testing, and liver biopsy led to prompt diagnosis. Treatment with glucocorticoids, anakinra, and hydroxychloroquine led to rapid clinical and laboratory improvement. This case illustrates how collaboration and prompt diagnosis and treatment can improve survival of patients with this life-threatening condition. INTRODUCTION Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening, frequently misdiagnosed condition of excess immune activation that can rapidly progress to multiorgan failure and death. HLH can be classified into primary and secondary. HLH secondary to autoimmune diseases is rare, with the prevalence of HLH being 12% among patients with autoimmune diseases.1 HLH secondary to systemic lupus erythematosus (SLE) is even rarer, with the prevalence of HLH being 0.9%–4.6% among patients with SLE.2–4 However, among the autoimmune triggers, SLE is the most common, accounting for 39% of cases, and HLH can be the first manifestation of SLE.1,5 Diagnosis is often delayed due to overlapping clinical and laboratory findings with infections and autoimmune diseases. We report a case of a young, healthy woman with HLH as the first manifestation of SLE. CASE REPORT A 21-year-old, South Asian woman with no significant past medical history presented to the emergency department with mouth pain, rashes on her face and back, and muscle aches. One month prior, she had seen her primary care physician for intermittent fevers, headaches, and diffuse muscle aches and joint stiffness. Routine laboratory results showed transaminase elevation (aspartate aminotransferase [AST] 70 IU/L, alanine aminotransferase [ALT] 55 IU/L, alkaline phosphatase 59 IU/L, and total bilirubin 0.5 mg/dL), mild leukopenia of 3,300 cells/µL, and positive cytomegalovirus IgM antibody. Testing for hepatitis viruses and Lyme was negative. One week before presentation, she also developed mouth pain and rashes on her face and back. Repeat outpatient laboratory results 1 day before presentation showed worsening transaminase elevation with AST 545 IU/L and ALT 499 IU/L, worsening leukopenia of 1,500 cells/µL, and new thrombocytopenia of 133,000/µL, and she was advised to go to the emergency department. Upon arrival, vitals were normal. Physical examination showed lip swelling, gingivitis, and papulonodular lesions on the face, hands, and upper back. The transaminase elevation, leukopenia, and thrombocytopenia continued to worsen. CT of the abdomen and pelvis with contrast was unremarkable. Multiple specialists were consulted: hepatology, infectious disease, dermatology, hematology, and rheumatology. Comprehensive viral, tickborne, and autoimmune hepatitis antibody testing was sent (Table 1). Cytomegalovirus polymerase chain reaction was negative. Epstein-Barr virus IgG antibody was positive, but IgM antibody and polymerase chain reaction were negative. Punch biopsy of the rash on her back showed folliculitis. Antinuclear antibody titers were strongly positive at 1:5,120, antismooth muscle antibody was positive at 29, and IgG antibody was positive at 1,862. Liver biopsy was performed the next day to rule out autoimmune hepatitis. Elevated ferritin was noted at 6,015 ng/mL, which was thought to be secondary to hepatic inflammation; however, HLH testing was sent as well. Table 1.Laboratory findingsVariableValueReference rangeCMV PCRNegativeCMV IgM antibodyPositiveCMV IgG antibodyNegativeEBV PCRNegativeEBV IgM antibodyNegativeEBV IgG antibodyPositiveHepatitis B core antibodyNegativeHepatitis B surface antigenNegativeHepatitis C antibodyNegativeHepatitis E IgM antibodyNegativeHepatitis E IgG antibodyNegativeHHV6 IgM antibodyNegativeHHV6 IgG antibodyNegativeHSV PCR (skin/mouth biopsy)NegativeVZV PCRNegativeLyme IgM antibodyNegativeLyme IgG antibodyNegativeEhrlichiaNegativeAnaplasmaNegativeHIVNegativeGonorrheaNegativeChlamydiaNegativeAntinuclear antibody1:5,120Antismooth muscle antibodyPositiveAntimitochondrial antibodyNegativeLiver kidney microsomal antibody type 1NegativeSoluble liver antigenNegativeCeruloplasmin20.6IgG antibody (mg/dL)1862610-1,620IgA antibody (mg/dL)18984–500IgE antibody (KU/L)797<214IgM antibody (mg/dL)13735–242Ferritin (ng/mL)6,01510–282Triglycerides (mg/dL)113<150CD25 (pg/mL)6,618214–1910Fibrinogen (mg/dL)<150205–518Lactate dehydrogenase (IU/L)1,114<171Reticulocyte count (%)0.50.4–2.4Haptoglobin (mg/dL)<3036–195D-dimer (μg/mL)2.70.00–0.49Direct CoombsPositiveC-reactive protein (mg/dL)<0.5<0.8Erythrocyte sedimentation rate (mm/h)60–40Rheumatoid factor (IU/mL)13<12.5Cyclic citrullinated peptide0.5Creatine phosphokinase (IU/L)1,2560–200Aldolase (U/L)17.1<8.1Antihistone antibody (U)9<1Complement 3 (mg/dL)3381–157Complement 4 (mg/dL)613–39CH50 (U/mL)<1031–60Antidouble stranded DNA (IU/mL)333<10Anti-SmithNegativeRibonucleoproteinNegativeAnti-Sjögren's syndrome ANegativeAnti-Sjögren's syndrome BNegativeCXCL9 pg/mL3,498<769CXCL10 pg/mL184047–382Interferon-γ (pg/mL)16.9<15.6Interleukin-1 β (pg/mL)<0.8<3.9Interleukin-4 (pg/mL)11.6<1.1Interleukin-6 (pg/mL)19.4<13.4Interleukin-10 (pg/mL)21.5<7.8Interleukin-18 (pg/mL)1,03482–344Tumor necrosis factor-α (pg/mL)56.8<15.6CMV, cytomegalovirus; EBV, Epstein-Barr virus; HHV, human herpesvirus; HIV, human immunodeficiency virus; HSV, herpes simplex virus; PCR, polymerase chain reaction; VZV, varicella-zoster virus. Laboratory findings CMV, cytomegalovirus; EBV, Epstein-Barr virus; HHV, human herpesvirus; HIV, human immunodeficiency virus; HSV, herpes simplex virus; PCR, polymerase chain reaction; VZV, varicella-zoster virus. The patient's symptoms slowly worsened. Her mouth pain was significantly limiting her oral intake, and her laboratory results continued to worsen: liver function tests peaked at AST 1,259 IU/L and ALT 825 IU/L, white blood cell count reached a nadir of 900 cells/µL, and platelet count reached a nadir of 66,000/µL (Figures 1–3). Her liver biopsy showed focal hemophagocytosis with minimal portal inflammation and no perivenulitis (Figure 4). There were no plasma cell infiltrates or other features to suggest autoimmune hepatitis. Her laboratory findings also showed low fibrinogen at <150 mg/dL and elevated CD25 at 6,618 pg/mL. Given these findings, the patient was started on intravenous methylprednisolone and anakinra. Her constitutional and mucocutaneous symptoms, transaminase elevation, leukopenia, and thrombocytopenia started to improve (Figures 1–3). She never developed jaundice or coagulopathy. Trend of liver function tests. ALT, alanine aminotransferase; AST, aspartate aminotransferase. Trend of white blood cell count. Trend of platelet count. (A) Hematoxylin and eosin (20×) demonstrates apoptotic hepatocytes and Kupffer cell hypertrophy. (B) CD68 immunohistochemical stain (10×) highlights profound Kupffer cell hypertrophy. (C) Glycophorin immunohistochemical stain (40×) highlights red blood cells within a Kupffer cell. The patient did not fit the demographic for primary HLH, so additional autoimmune testing was sent for concern for secondary HLH, which showed low complements (C3 at 33 mg/dL and C4 at 6 mg/dL) and elevated antidouble stranded DNA at 333 IU/mL. Given the constellation of mucocutaneous symptoms, arthritis, leukopenia, thrombocytopenia, low complements, and elevated antidouble stranded DNA, a diagnosis of SLE was made. She was started on hydroxychloroquine. Her anakinra was tapered from 100 mg 4 times a day to 100 mg twice daily to ultimately, 100 mg daily. After 3 days of intravenous methylprednisolone, she was switched to 40 mg of oral prednisone daily, with a plan to taper by 10 mg every 2 weeks until she reaches a dose of 10 mg, after which she will taper by 2.5 mg every 2 weeks until finally reaching a dose of 5 mg daily. By the day of discharge, her liver function tests improved to AST 141 IU/L and ALT 299 IU/L, white blood cell count improved to 3,200 cells/µL, and platelet count improved to 197,000/µL (Figures 1–3). She was discharged on hydroxychloroquine, anakinra 100 mg daily, and a prednisone taper, with close outpatient follow-up with rheumatology. DISCUSSION HLH is a life-threatening condition caused by excess activation of cytotoxic T lymphocytes, natural killer cells, and macrophages, leading to excess production of proinflammatory mediators, ultimately leading to cytokine storm and subsequent multiorgan failure. HLH can be classified into primary and secondary. Secondary HLH is triggered by infections, immunodeficiencies, malignancies, and rarely, autoimmune diseases, most commonly SLE.2,3,6 A few case reports and 1 case series exist on HLH as the first manifestation of SLE in young men and women.1–3 However, this case is unique in our patient's South Asian ethnicity, the absence of cutaneous or cardiac involvement, our use of anakinra, and our patient's rapid clinical improvement. The HLH-2024 diagnostic criteria for HLH are fevers, splenomegaly, cytopenia of at least 2 cell lines, hypofibrinogenemia, hyperferritinemia, hypertriglyceridemia, elevated soluble CD25, and hemophagocytosis on bone marrow or tissue biopsy.7 A diagnosis of HLH requires either meeting at least 5 of these 8 criteria or having a molecular diagnosis consistent with HLH. Our patient met the following 6 criteria: fevers, cytopenia of at least 2 cell lines, hypofibrinogenemia, hyperferritinemia, elevated soluble CD25, and hemophagocytosis on tissue biopsy. Once the diagnosis of HLH is established, prompt immunological testing for SLE is necessary. The 2019 European League Against Rheumatism/American College of Rheumatology diagnostic criteria for SLE are: positive antinuclear antibody of at least 1:80 and weighted criteria from 7 clinical (constitutional, hematologic, neuropsychiatric, mucocutaneous, serosal, musculoskeletal, and renal) and 3 immunological (antiphospholipid antibodies, complements, and SLE-specific antibodies) domains.8 Each criterion is weighted from 2 to 10. A diagnosis of HLH requires a score of at least 10. Our patient scored 33. Treatment of HLH secondary to SLE is multidisciplinary, involving SLE-specific therapies, potential HLH-specific therapies based on severity, and symptom management. Clinically stable patients may respond to SLE-specific therapies of high-dose glucocorticoids and immunosuppressants, such as hydroxychloroquine, alone.9 Etoposide, intravenous immune globulin, or anakinra (an interleukin-1 antagonist) are often added. Anakinra was used in our patient for its higher response rates in non-malignant HLH, targeted mechanism, and lower toxicity.10 For severe or refractory cases, cyclosporine, ruxolitinib (a Janus kinase inhibitor), or emapalumab (an interferon-gamma inhibitor) may be added. Supportive care involves appropriate transfusions and prevention and treatment of bleeding and opportunistic infections. Secondary HLH has mortality rates of 30-40% within the first 2 months of diagnosis.11 Therefore, close monitoring for signs of organ dysfunction and for treatment response is crucial. In conclusion, this case encourages clinicians to consider HLH as a potential first manifestation of SLE. This case highlights how early multispecialist involvement, comprehensive laboratory testing, and potential tissue biopsy are essential to prompt diagnosis and treatment, which can improve symptoms and survival of patients with this otherwise life-threatening condition. DISCLOSURES Author contributions: S. Tummala, A. Wu, Y. Lin, and S. Celaj participated significantly in the conceptualization, design, drafting, and revising of the manuscript. T. Price and A. Demetris participated significantly in the procurement of pathology slides and conceptualization and drafting of the manuscript. All authors approved the manuscript as submitted. S. Tummala is the article guarantor. Financial disclosure: None to report. Informed consent was obtained for this case report.